Serpin-C1 / SERPINC1 / Antithrombin-III Antibody (Antigen Affinity Purified)

SerpinC1 / SERPINC1 / Antithrombin-III Antibody ( Antigen Affinity Purified )

SerpinC1 / SERPINC1 / Antithrombin-III Antibody Product Information

• Immunogen: Recombinant human Serpin C1 protein ( Catalog#10142-H08H )
• Antibody Type: Rabbit Polyclonal Antibody ( Antibody Purification Platform )
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: Produced in rabbits immunized with purified, human cell-derived, recombinant human SerpinC1 / SERPINC1 ( rh Serpin C1 ; Catalog#10142-H08H ; NP_000479.1 ; Met 1 - Lys 464 ). Serpin C1 specific IgG was purified by human Serpin C1 affinity chromatography.

SerpinC1 / SERPINC1 / Antithrombin-III Antibody Usage Guide

• Specificity: Human SerpinC1 / SERPINC1 / Antithrombin-III
• Western blot: This antibody can be used at 0.1 - 0.2 μg/mL with the appropriate secondary reagents to detect human SerpinC1 in WB. Using a DAB detection system, the detection limit for human SerpinC1 is approximately 2ng/lane under non-reducing conditions and 0.5 ng/lane under reducing conditions
• Direct ELISA: This antibody can be used at 0.5 -1.0 μg/mL with the appropriate secondary reagents to detect human SerpinC1. The detection limit for human SerpinC1 is 0.00245ng/well
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

SerpinC1 / SERPINC1 / Antithrombin-III Antibody Background

SerpinC1, also known as antithrombin III (AT III), is a member of the serpin superfamily of serine protease inhibitors. SerpinC1 synthesized in the liver is the principal plasma serpin of blood coagulation proteases and inhibits thrombin and other factors such as Xa by the formation of covalently linked complexes. In common with SerpinA5 and D1, the inhibitory activity of SerpinC1 undergoes a dramatic increase in the presence of heparin and other glycosaminoglycans. The deficiency or functional abnormality of ATIII may result in an increased risk of thromboembolic disease, such as deep vein thrombosis and pulmonary embolism. In addition, it has been reported that SerpinC1 can alter or influence inflammatory processes via inhibition of NF-κB activation or actin polymerization.

References

1. Chandra, T. et al., 1983, Proc. Natl. Acad. Sci. 80: 1845-1848.
2. Perry, D.J. et al., 1994, Blood. Rev. 8: 37-55.
3. Chuang, Y.J. et al., 2001, Biochemistry. 40: 6670-6679.
4. Saito, H. et al., 2005, J. Leukoc. Biol. 78: 777-784.
5. Oelschlager, C. et al., 2002, Blood. 99: 4015-4020.